JLPC(SH:600513) Ge Long Hui·2025-11-18 10:28Core Viewpoint - The company plans to sign a technical cooperation development contract with Nanjing University to jointly develop anti-thrombotic small nucleic acid drugs, with a total contract amount of 15 million RMB (including tax) [1] Company Summary - The company will pay the cooperation fees to Nanjing University in installments according to the project development plan outlined in the contract [1] - Upon successful development and market launch of the target drug, the company will pay Nanjing University a percentage of the annual revenue generated by the drug for a period of 10 years [1] - The collaboration aims to leverage Nanjing University's strong research capabilities in nucleic acid drugs and the company's industrialization and clinical development capabilities to advance the research and commercialization of innovative drugs [1] Industry Summary - The domestic small nucleic acid drug market is primarily dominated by imported drugs, indicating significant growth potential in the domestic market compared to the global market [1] - With increasing policy support and capital investment, the development of small nucleic acid drugs in China is progressing rapidly, and the domestic market is expected to experience rapid growth [1] - The company's early entry into the small nucleic acid drug field is aimed at seizing market opportunities, supported by a deep understanding of local market demands and the strategic alignment with its cardiovascular treatment focus [1]